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Abstract 
Aflapin
® is a novel synergistic composition derived from Boswellia serrata gum resin (Indian 
Patent Application No. 2229/CHE/2008). Aflapin is more efficacious as an anti-inflammatory 
agent compared to the existing Boswellia products, 5-Loxin
 and traditional 65% Boswellia 
extract. A 30-day, double-blind, randomized, placebo-controlled study was conducted to 
validate the efficacy of Aflapin
® in the management of clinical symptoms of osteoarthritis (OA) 
of the knee (Clinical trial registration number: ISRCTN69643551). Sixty eligible OA subjects 
selected through screening were included in the study. The subjects received either 100 mg 
(n=30) of Aflapin
® or placebo (n=30) daily for 30 days. Each subject was evaluated for pain and 
physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, 
and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), 
and at days 5, 15 and 30. A series of biochemical tests in serum, urine and hematological 
parameters established the safety of Aflapin. The observations suggest that Aflapin conferred 
clinically and statistically significant improvements in pain scores and physical function scores 
in OA subjects. Aflapin provided significant improvements in pain score and functional ability 
in as early as 5 days of treatment. In conclusion, our observations suggest that Aflapin is a safe, 
fast acting and effective alternative intervention in the management of OA. 
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Introduction 
Osteoarthritis  (OA)  is  a  degenerative  joint  dis-
order of articular cartilage and is the most common 
type of arthritis in elderly persons. In OA, breakdown 
of cartilage and synovial proliferation result in pain 
and stiffness of joints. [1-3]. It has been estimated that 
OA affects more than 27 million people in the United 
States alone and is the leading cause of physical disa-
bility and impaired quality of life in elderly world-
wide [4]. Unfortunately, till today there is no proper 
therapeutic  intervention  available  to  treat  OA.  Cur-
rently,  acetaminophen  and  non-steroidal  an-
ti-inflammatory  drugs  (NSAIDs)  including  cy-
clo-oxygenase II inhibitors are used for relief of pain 
and  stiffness  [5,6].  Although,  these  pharmaceutical 
agents reduce both pain and improve physical func-
tions  temporarily  without  healing  the  cartilage  and 
subchondral damage, long term usage of NSAIDs is 
associated with enhanced risk for renal insufficiency, 
gastrointestinal  bleeding,  hypertension  and  conges-
tive heart failure [6-8]. Because of the high incidence 
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of  adverse  events  associated  with  NSAID  therapy, 
effective  and  safer  alternative  treatments  for  the 
management of OA pain are highly desirable.  
In recent years, the gum resin extracted from the 
ancient herb, Boswellia serrata has gained considerable 
attention as a potent anti-inflammatory, anti-arthritic 
and  analgesic  agent  [9,10].  3-O-Acetyl-11-keto-beta- 
boswellic acid (AKBA) is the most active compound 
of  Boswellia  extract  and  is  a  potent  inhibitor  of 
5-lipoxygenase (5-LOX), a key enzyme in the biosyn-
thesis  of  leukotrienes  from  arachidonic  acid  in  the 
cellular  inflammatory  cascade  [11,12].  A  number  of 
independent  clinical  studies  support  the  an-
ti-inflammatory  and  anti-arthritic  properties  of  Bos-
wellia extracts [13-16].  
Aflapin® is a novel synergistic composition de-
rived  from  Boswellia  serrata  gum  resin 
(PCT/IN2009/000505) [17-19]. Interestingly, the oral 
bioavailability of AKBA from Aflapin was found to be 
significantly higher in comparison with that of com-
mercially  available  Boswellia  extracts  [17].  Aflapin 
exhibited  enhanced  5-lipoxygenase  inhibition  in  en-
zyme based in vitro assay and Matrix Metalloprotein-
ase 3 (MMP3) inhibition in pro-inflammatory cytokine 
induced human primary chondrocytes. In a compara-
tive analysis, various in vitro and in vivo studies have 
established that in comparison with regular Boswellia 
extracts  Aflapin  possesses  more  powerful  an-
ti-inflammatory efficacy and exhibits better recovery 
of  glycosaminoglycans  (GAG)  in  pro-inflammatory 
cytokine  induced  human  chondrocytes.  [17].  Fur-
thermore, safety studies conducted according to Or-
ganization for Economic Co-operation and Develop-
ment (OECD) guidelines manifested the overall safety 
of Aflapin in animal models [18]. 
In a 90-day placebo controlled clinical study the 
anti-arthritic efficacy of Aflapin was evaluated in OA 
subjects. Aflapin demonstrated a significant reduction 
in pain and improvement in the quality of life in OA 
subjects [19]. Supplementation of 100 mg Aflapin/day 
conferred  significant  improvements  in  pain  scores 
and physical function. These observations led us to 
substantiate the anti-OA efficacy of Aflapin in a se-
cond  independent  clinical  study.  We  conducted  an 
independent double blind placebo controlled trial in a 
different set of subjects with OA. This study design 
was intended to evaluate, (i) the anti-OA efficacy of 
Aflapin  and  (ii)  to  assess  whether  Aflapin  supple-
mentation can provide fast relief from clinical symp-
toms of OA. The present communication describes the 
anti-OA efficacy of Aflapin, which substantiates the 
earlier  observation;  and  demonstrates  that  Aflapin 
provides significant pain relief in subjects with OA in 
as early as 5 days of treatment.  
Materials and Methods 
Study material 
Aflapin is a novel synergistic composition con-
taining  B.  serrata  extract  selectively  enriched  with 
AKBA and B. serrata non-volatile oil. The non-volatile 
oil  was  prepared  by  selective  removal  of  Boswellic 
acids  followed  by  removing  volatiles  under  high 
vacuum  (PCT  application  #  PCT/IN2009/000505). 
This composition was standardized to contain at least 
20% AKBA. 
Research design 
This  randomized,  double-blind,  placebo  con-
trolled  trial  was  conducted  during  August  2009  to 
December 2009. The study protocol was approved by 
the Institutional Review Board (IRB) of Alluri Sitara-
ma  Raju  Academy  of  Medical  Sciences  (ASRAM), 
Eluru, Andhra Pradesh, India (Clinical Trial Registra-
tion No. ISRCTN69643551).  
Subjects 
One  hundred  and  fifty  two  patients  of  either 
gender  were  selected  for  screening.  They  were  be-
tween 40 and 80 years of age, and had been suffering 
from unilateral or bilateral OA of the knee according 
to  the  criteria  of  the  American  College  of  Rheuma-
tology [20] for more than 3 months. After the use of 
usual medications had ceased for 7 days, the visual 
analog scale (VAS) score that assessed pain during the 
most painful knee movement had to be more than 40, 
and Lequesne's functional index [21] had to be over 7 
points. Participants had to be able to walk and give 
both  verbal  and  written  information  regarding  the 
study. Signed informed consent was obtained prior to 
entry.  Exclusion  criteria  included  an  underlying  in-
flammatory arthropathy, hyperuricemia, expectation 
of surgery in the near future, recent injury in the area 
affected  by  OA  of  the  knee,  intra-articular  cortico-
steroid injections within the last 3 months, hypersen-
sitivity to NSAIDs, abnormal liver or kidney function 
tests,  major  abnormal  finding  on  complete  blood 
count,  history  of  coagulopathies,  history  of  peptic 
ulceration  and  upper  GI  hemorrhage,  uncontrolled 
hypertension, congestive heart failure, hyperkalemia, 
pregnancy, lactation and malignant tumors.  
Randomization and treatment 
A total of 60 subjects with symptoms of mild to 
moderate  OA  were  selected  and  recruited  into  the 
study.  Each  subject  was  randomly  assigned  to  the 
treatment group or placebo group using a randomi-
zation  table  generated  using  validated  computer 
software  CODE;  IDV,  Gauting,  Germany.  The  ran-Int. J. Med. Sci. 2011, 8 
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domization  codes  were  secured  confidential  by  the 
clinical trial pharmacist and statistician. Thirty sub-
jects  were  allocated  each  into  placebo  and  Aflapin 
groups. The subjects in Aflapin group received 50 mg 
of  encapsulated  Aflapin®  twice  daily,  whereas,  the 
subjects in the placebo group received two capsules 
having  similar  organoleptic  properties  including 
weight, taste, color, odor and feel. Each subject filled a 
questionnaire,  providing  details  regarding  de-
mographics, medical history and nutritional status, at 
the  baseline  evaluation  and  during  each  follow-up 
evaluation on days 5, 15 and 30.  
Assessments 
Functional  disability  was  assessed  at  baseline 
and at all follow-up visits (days 5, 15 and 30) by the 
investigators.  Pain,  stiffness  and  physical  function 
were assessed using Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) [22], LFI 
[21] and VAS [23] scores. The pain, stiffness and func-
tion subscales of the WOMAC were normalized to a 
scale  of  0  to  100  units  [24].  Analyses  of  these 
end-points  were  based  upon  the  time-weighted  av-
erage change from baseline over 30 days.  
For assessment of safety of Aflapin®, several pa-
rameters were evaluated in serum, urine and whole 
blood of all subjects at each visit of the study duration 
(Table 1). Serum biochemical parameters and hema-
tological  parameters  were  measured  using  an  auto-
mated analyzer (HumaStar 300) and a hematological 
counter (Humacount, Human, Wiesbaden, Germany). 
The  urine  analysis  was  carried  out  using  UroCol-
or™10 Dip Sticks and Urometer 600 (Standard Diag-
nostics, Kyonggi-do, Korea) and by sediment analysis 
using microscopy.  
Rescue medication 
Subjects were prescribed 400 mg ibuprofen tab-
lets (maximum 400 mg thrice daily; total 1,200 mg) as 
rescue analgesia during the study based on pain in-
tensity reported to the study physician by some sub-
jects.  Those  subjects  were  advised  not  to  take  the 
rescue medicine at least 3 days before each evaluation. 
No other pain relieving interventions  were allowed 
during the study period.  
Statistical analysis 
Detailed statistical analyses were performed us-
ing SAS software to evaluate the efficacy of Aflapin in 
comparison with the placebo group in terms of im-
provement  in  pain  and  physical  function  scores  at 
baseline and on days 5, 15 and 30 of treatment. Wil-
coxon's signed-rank test was used for inter group and 
intra-group  comparisons  of  pain  scores.  Pair-wise 
changes were examined by carrying out least signifi-
cant difference (LSD) test for all possible pairs. The 
significance of the effects of the treatment groups was 
compared  by  using  one-way  analysis  of  variance 
(ANOVA) followed by Tukey's multiple comparison 
tests. Results with P<0.05 are considered statistically 
significant. This is a two-arm (Aflapin and placebo), 
randomized,  double-blind,  placebo-controlled,  sin-
gle-centre  trial  conducted  over  30  days.  The  trial's 
primary  objective  was  to  validate  the  efficacy  of 
Aflapin on reduction of pain, joint stiffness and im-
provement in physical function in subjects with oste-
oarthritis of knee. 
 
 
 
Table 1: Parameters tested in Serum, urine and whole 
blood samples  
Biochemical Parameters 
Blood sugar 
Alkaline phosphatase 
SGOT  
SGPT  
Total Bilirubin 
Direct Bilirubin  
CK Nac  
Creatinine  
Total Protein  
Triglycerides  
Cholesterol  
HDL, LDL 
Urea 
Hematology 
Total Leukocyte count 
Total RBC count 
Hemoglobin % 
Mean Corpuscular volume (MCV) 
Mean corpuscular hemoglobin (MCH) 
Mean corpuscular hemoglobin Concentration 
Platelet count 
Differential count (DC) 
Urine Analysis 
Blood 
Bilirubin, Urobilinogen 
Ketone 
Protein 
Nitrite 
Glucose 
pH, Specific gravity 
Leucocytes 
Pus cells, Epithelial cells, Crystals 
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Results 
Baseline characteristics 
The subjects were randomly distributed into two 
groups  and  the  descriptive  statistics  comparing  de-
mographic variables, baseline disease characteristics 
and baseline outcome measures (LFI, VAS, WOMAC 
pain, function and stiffness sub-scores) are provided 
in  Table  2.  The  demographic  variables,  dis-
ease-related and baseline outcome parameters of two 
groups,  one  receiving  Aflapin®  100  mg/day  (n=30) 
and the other receiving placebo (n=29) did not differ 
significantly at baseline.  
 
Table 2: Characteristics of patients in study groups. 
Characteristics  Placebo (n = 29)  100 mg/day 
Aflapin® (n = 30) 
Sex (male/female; n)  11/18  11/19 
Age (years)  55.3 ± 8.8  53.2 ± 6.5 
Body weight (kg)  59.7 ± 10.5  61.9 ± 10.9 
Body mass index 
(kg/m2) 
24.9 ± 2.6  25.7 ± 3.3 
Visual analog score  47.6 ± 9.7  48.0 ± 6.0 
Lequesne's Func-
tional Index 
12.5 ± 3.4  12.8 ± 3.7 
WOMAC score     
 Pain subscale  45.9 ± 10.5  47.8 ± 12.4 
 Stiffness subscale  37.5 ± 14.9  38.8 ± 13.3 
 Function subscale  40.6 ± 9.5  41.1 ± 11.8 
 
 
Clinical efficacy 
The  data  regarding  the  normalized  pain  and 
function scores are summarized in Table 3. At the end 
of the study, significant reductions in pain and func-
tion  scores  were  observed  in  treatment  group  sup-
plemented with 100 mg/day of Aflapin when com-
pared to either baseline or placebo.  
Significant  (p<0.05)  reduction  in  all  the  pain 
scores was observed in the Aflapin group by day 30, 
when compared to the placebo group. In comparison 
with placebo, supplementation of Aflapin for 30 days 
conferred 37.6, 32.0, 40.1, 41.3 and 38.8 percent reduc-
tions in VAS, LFI, WOMAC pain, WOMAC stiffness 
and WOMAC function scores, respectively. Interest-
ingly, significant (p<0.05) reductions in VAS and LFI 
scores were also observed in Aflapin group over pla-
cebo by day 5. Aflapin supplementation showed 14.8 
and  16.3  percent  better  reduction  in  VAS  and  LFI 
scores respectively over placebo by 5th day. Compared 
to  the  placebo  group,  the  reductions  in  WOMAC 
scores were not significant after 5 days of treatment. 
Aflapin supplementation for 30 days afforded highly 
significant (p<0.001) reductions in all the pain scores 
exhibiting  49.1,  34.4,  49.5,  48.4  and  45.2  percent  re-
duction, in VAS, LFI, WOMAC pain, WOMAC stiff-
ness and WOMAC function scores, respectively, when 
compared  to  the  baseline.  However,  significant 
(p<0.05) reductions were observed in VAS, WOMAC 
pain and WOMAC function scores in placebo group 
when compared to the base line and the magnitude of 
the reductions are 17.6, 12.0 and 9.24 percent respec-
tively; which are small in comparison with those of 
the Aflapin group (figure 2). 
Table 3. Normalized pain and function scores. 
Parameter and treatment   Baseline mean ± SD  Day-30 mean ± SD  p value (vs. baseline)  p value (vs. placebo) 
Visual analogue scale score         
Placebo (n=29)  47.6 ± 9.7  39.3 ± 9.5  <0.0001  NA 
Aflapin 100 mg/day (n=30)  48.0 ± 6.0  24.5 ± 11.9  <0.0001  <0.0001 
Lequesne's Functional Index         
Placebo (n=29)  12.5 ± 3.4  12.4 ± 2.6  0.7646  NA 
Aflapin 100 mg/day (n=30)  12.8 ± 3.7  8.4 ± 3.8  <0.0001  <0.0001 
WOMAC pain subscale         
Placebo (n=29)  45.9 ± 10.5  40.3 ± 11.4  0.001  NA 
Aflapin 100 mg/day (n=30)  47.8 ± 12.4  24.2 ± 12.0  <0.0001  <0.0001 
WOMAC stiffness subscale         
Placebo (n=29)  37.5 ± 14.9  34.1 ± 15.6  0.2024  NA 
Aflapin 100 mg/day (n=30)  38.8 ± 13.3  20.0 ± 15.6  <0.0001  0.0014 
WOMAC function subscale         
Placebo (n=29)  40.6 ± 9.5  36.8 ± 11.5  0.0029  NA 
Aflapin 100 mg/day (n=30)  41.1 ± 11.8  22.5 ± 11.1  <0.0001  <0.0001 
NA, not applicable; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. Int. J. Med. Sci. 2011, 8 
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Figure 1:  Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, 
serum biochemistry, hematology, urine biochemistry and pro-inflammatory biomarkers were done at baseline (day 0) and 
on days 5, 15 and 30 during follow up.  
 
 
 
 
Figure 2:  Pain, Function and stiffness 
scores. Presented are the mean scores 
for (a) visual analog scale, (b) Leques-
ne's  Functional  Index,  (c)  Western 
Ontario  and  McMaster  Universities 
Osteoarthritis Index (WOMAC)-pain, 
(d)  WOMAC-stiffness,  and  (e) 
WOMAC-function in placebo and 100 
mg/day  Aflapin®  groups  at  different 
time points day 0, day 5, day 15 and day 
30.  Each  bar  represents  mean  ± 
standard deviation. In comparison with 
placebo  the  mean  scores  in  the 
treatment  groups  were  tested  for 
significance using Wilcoxon's rank-sum 
test; * p < 0.05 and # p < 0.01. 
 
   Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
620 
Biochemical evaluations 
As  a  part  of  the  safety  evaluation,  laboratory 
tests were performed for assessment of different bio-
chemical parameters (in serum and urine) and hema-
tological parameters. The repeated measure ANOVA 
was used to compare the values at different evalua-
tions over the 30 days period with those of baseline. 
Statistical analyses of these parameters did not indi-
cate any significant changes. Although minor changes 
were  observed  in  some  of  the  parameters,  they  re-
mained within the normal laboratory range. Similarly, 
no significant changes in hematological and urinary 
parameters  were  observed  in  the  active  treatment 
groups  when  compared  to  the  placebo  (data  not 
shown).  
Adverse Events and Dropouts 
During the course of the 30-day study, no major 
adverse events were reported. However, nausea and 
headache were reported as minor adverse events by 
two subjects during the study; one each from placebo 
and Aflapin supplemented groups.  
One subject from placebo groups was dropped 
out from the study due to un-availability for the fol-
low up evaluations.  
Discussion 
The primary objective of conducting the present 
study  was  to  substantiate  the  observation  that 
Aflapin,  a  novel  Boswellia  extract  reduces  clinical 
symptoms of osteoarthritis, pain, physical discomfort. 
Boswellia serrata is an ancient Indian medicinal plant, 
and the gum resin of this plant has long been known 
for  anti-inflammatory,  anti-arthritic  and  analgesic 
properties  [9,10].  Earlier  studies  indicate  that 
3-O-Acetyl-11-keto-beta-boswellic acid (AKBA) is the 
most active principle present in the Boswellia extracts, 
which  mainly  contributes  the  anti-inflammatory  ac-
tivities  of  this  herbal  extract  by  inhibiting 
5-lipoxygenase activity [11,12].  
To date, the anti-inflammatory and anti-arthritic 
efficacy of different forms of Boswellia extracts have 
been established in various models either in vitro or in 
vivo or in clinical studies [13-16,19,25-30]. However, 
studies  indicate  that  upon  oral  administration,  Bos-
wellia  extracts  exhibit  poor  intestinal  absorption  of 
AKBA  and  poor  bioavailability  which  limits  its  an-
ti-inflammatory  efficacy  [31,32].  Aflapin  is  a  novel 
synergistic composition, which contains B. serrata ex-
tract enriched to 20% AKBA and B. serrata non-volatile 
oil (PCT/IN2009/000505). In a recent communication 
Sengupta et al [17] have reported that Aflapin® pro-
vides 51.78% more bioavailable concentration of sys-
temic AKBA after a single dose oral administration in 
comparison with 30% AKBA enriched Boswellia ex-
tract (5-Loxin®). In corroboration, it was observed in a 
recent  double  blind  placebo  controlled  study  that 
Aflapin provides significantly better improvements in 
clinical  symptoms  in  OA  subjects  when  compared 
with 30% AKBA enriched Boswellia extract (5-Loxin®) 
[19]. The present 30-day double blind, placebo con-
trolled  clinical  study  was  designed  with  two  ap-
proaches; (i) to reassess the anti-arthritic efficacy of 
Aflapin and (ii) to evaluate the early onset of action of 
Aflapin in pain reduction and improvement of phys-
ical function in OA subjects.  
The present study demonstrates the potential of 
Aflapin  in  alleviating  pain,  joint  stiffness  and  im-
proving physical functions in OA subjects (Figure 2). 
Pain, stiffness of joints, reduced joint movement and 
physical discomfort are the major clinical manifesta-
tions of OA [24,29,30]. In comparison with the place-
bo, at the end of the study, the Aflapin supplemented 
group showed statistically significant improvements 
in all pain scores including VAS, LFI, WOMAC pain, 
WOMAC  stiffness  and  WOMAC  function  scores 
(Figure 2). Aflapin provided significant reductions in 
pain  scores  of  VAS  and  LFI  in  as  early  as  5  days. 
Whereas, in the previous study Aflapin demonstrated 
significant  relief  from  joint  pain  and  physical  dis-
comfort in OA subjects after 7 days of treatment [19]. 
Together, these findings clearly suggest that Aflapin 
confers quick and significant pain relief, improvement 
in physical ability and quality of life in OA subjects.  
Therapeutic efficacy and fast action of Aflapine 
can be attributed to its role in intervening the cellular 
and molecular mechanisms associated with the path-
ologic processes of OA. Earlier we have demonstrated 
multiple beneficial effects of Aflapin over 5-Loxin; (1), 
better anti-inflammatory efficacy of Aflapin through 
inhibiting 5-lipoxygenase enzyme activity, and inhib-
iting TNFα production; (2), provides significant pro-
tection from damaging action of IL-1 by increasing 
chondrocytes proliferation and increasing synthesis of 
cartilage matrix substances such as collagen and gly-
cosaminoglycans  in  human  primary  chondrocytes; 
(3), Aflapin also inhibits MMP3 production in TNFα 
induced human chondrocytes [17]. 
Overall,  the  data  demonstrate  the  efficacy  of 
Aflapin  in  pain  management,  improving  physical 
function, quality of life and joint health. Presumably, 
the pleotropic beneficial effects of Aflapin might pro-
vide potential anti-osteoarthritic efficacy, which helps 
improving joint health in OA subjects [17,19,25].  
In  corroboration  with  the  previous  studies 
[19,25], the present investigation does not show any 
major  changes  in  the  hematological  parameters,  se-
rum biochemical parameters and in urine analysis in Int. J. Med. Sci. 2011, 8 
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Aflapin  supplemented  subjects  in  comparison  with 
placebo. In addition, no major adverse effect has been 
reported by the subjects included in Aflapin group. 
Taken  together,  these  observations  further  demon-
strate and substantiate the anti-osteoarthritic potential 
of Aflapin.  
Conclusion 
In summary, the present study validates the po-
tential anti-OA efficacy and safety of Aflapin. In ad-
dition the present study also establishes the fast onset 
of  therapeutic  action  of  Aflapin®  in  OA  subjects. 
Aflapin significantly improves joint function and re-
lieves  pain  at  as  early  as  5  days  of  treatment.  This 
study bears potential promise in favor of Aflapin as a 
useful  alternative  therapeutic  strategy  for  the  man-
agement of OA in humans. 
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